Latest period
$157.90M
YoY change
-57.3%
5Y CAGR
-18.4%
Peak year (2013)
$3.51B
Cumulative CapEx
$12.52B
CapEx history chart for Biogen (BIIB) from 1989 to 2025
Latest: $153.80M
CapEx growth chart for Biogen (BIIB) from 1989 to 2025
Latest: -57.3%
CapEx history table for Biogen (BIIB) from 1989 to 2025
| 2025 | $153.80M | -57.3% | −$206.00M | ||
| 2024 | $359.80M | +15.5% | +$48.40M | ||
| 2023 | $311.40M | +29.6% | +$71.10M | ||
| 2022 | $240.30M | -6.9% | −$17.80M | ||
| 2021 | $258.10M | -39.2% | −$166.70M | ||
| 2020 | $424.80M | -17.4% | −$89.70M | ||
| 2019 | $514.50M | -33.2% | −$256.10M | ||
| 2018 | $770.60M | -11.2% | −$96.80M | ||
| 2017 | $867.40M | +40.8% | +$251.30M | ||
| 2016 | $616.10M | -4.2% | −$26.90M | ||
| 2015 | $643.00M | +123.4% | +$355.20M | ||
| 2014 | $287.80M | -91.8% | −$3.22B | ||
| 2013 | $3.51B | +1278.5% | +$3.25B | ||
| 2012 | $254.55M | +0.9% | +$2.37M | ||
| 2011 | $252.18M | +45.7% | +$79.12M | ||
| 2010 | $173.06M | +4.5% | +$7.41M | ||
| 2009 | $165.65M | -40.0% | −$110.31M | ||
| 2008 | $275.95M | -2.9% | −$8.15M | ||
| 2007 | $284.11M | +43.3% | +$85.79M | ||
| 2006 | $198.31M | -37.7% | −$120.06M | ||
| 2005 | $318.38M | -13.9% | −$51.39M | ||
| 2004 | $369.76M | +22.7% | +$68.52M | ||
| 2003 | $301.25M | +81.6% | +$135.34M | ||
| 2002 | $165.90M | -15.2% | −$29.63M | ||
| 2001 | $195.53M | -1.8% | −$3.58M | ||
| 2000 | $199.12M | +130.7% | +$112.79M | ||
| 1999 | $86.33M | +156.8% | +$52.72M | ||
| 1998 | $33.61M | -5.5% | −$1.94M | ||
| 1997 | $35.55M | -45.8% | −$30.09M | ||
| 1996 | $65.64M | +30.5% | +$15.33M | ||
| 1995 | $50.31M | +15.2% | +$6.64M | ||
| 1994 | $43.67M | +304.4% | +$32.87M | ||
| 1993 | $10.80M | +14.9% | +$1.40M | ||
| 1992 | $9.40M | +11.9% | +$1.00M | ||
| 1991 | $8.40M | -24.3% | −$2.70M | ||
| 1990 | $11.10M | +258.1% | +$8.00M | ||
| 1989 | $3.10M | — | — |
- 2025$153.80M-57.3%
- 2024$359.80M+15.5%
- 2023$311.40M+29.6%
- 2022$240.30M-6.9%
- 2021$258.10M-39.2%
- 2020$424.80M-17.4%
- 2019$514.50M-33.2%
- 2018$770.60M-11.2%
- 2017$867.40M+40.8%
- 2016$616.10M-4.2%
- 2015$643.00M+123.4%
- 2014$287.80M-91.8%
- 2013$3.51B+1278.5%
- 2012$254.55M+0.9%
- 2011$252.18M+45.7%
- 2010$173.06M+4.5%
- 2009$165.65M-40.0%
- 2008$275.95M-2.9%
- 2007$284.11M+43.3%
- 2006$198.31M-37.7%
- 2005$318.38M-13.9%
- 2004$369.76M+22.7%
- 2003$301.25M+81.6%
- 2002$165.90M-15.2%
- 2001$195.53M-1.8%
- 2000$199.12M+130.7%
- 1999$86.33M+156.8%
- 1998$33.61M-5.5%
- 1997$35.55M-45.8%
- 1996$65.64M+30.5%
- 1995$50.31M+15.2%
- 1994$43.67M+304.4%
- 1993$10.80M+14.9%
- 1992$9.40M+11.9%
- 1991$8.40M-24.3%
- 1990$11.10M+258.1%
- 1989$3.10M—
CapEx values are taken from Biogen's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About CapEx at Biogen (BIIB)
According to Biogen's latest reported financial statements, the company's current CapEx (TTM) is $157.90M. Capital expenditures (CapEx) are cash outlays for property, plant, and equipment and other long-lived productive assets — reported on the cash flow statement under investing activities. CapEx funds future capacity (factories, data centers, software, machinery), so rising spend can signal investment in growth, while heavy CapEx reduces free cash flow available to shareholders. We display CapEx as a positive amount (the absolute cash outflow); compare with revenue to gauge capital intensity and with total assets for the asset-base context.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
In 2025, Biogen (BIIB) CapEx totalled $153.80M – plunged 57.3% year-over-year.
Biogen CapEx compound annual growth for the 2020–2025 (5 years) window is -18.4%, with a net decline across the window.
Biogen CapEx plunged from $3.51B in 2013 to $153.80M in 2025, a 95.6% drawdown.
2013 marks the peak CapEx at $3.51B, with the historical low of $3.10M recorded in 1989.
Biogen Capital Expenditures by Year
Biogen Capital Expenditures 2025: $153.80M
Biogen posted CapEx of $153.80M in 2025, plunged 57.3% below 2024.
Biogen Capital Expenditures 2024: $359.80M
In 2024, Biogen reported CapEx of $359.80M, grew 15.5% from 2023.
Biogen Capital Expenditures 2023: $311.40M
Biogen CapEx in 2023 was $311.40M, grew 29.6% from 2022.
Biogen Capital Expenditures 2022: $240.30M
2022's CapEx for Biogen came in at $240.30M, declined 6.9% below 2021.
Biogen Capital Expenditures 2021: $258.10M
Biogen CapEx in 2021 was $258.10M.
See more financial history for Biogen (BIIB).
Sector peers by CapEx
Healthcare peers of Biogen (BIIB), ranked by their latest CapEx
| $14.05B | |
| $7.84B | |
| $4.83B | |
| $4.11B | |
| $3.62B | |
| $2.81B | |
| $1.86B | |
| $1.21B |
- $14.05B
- $7.84B
- $4.83B
- $4.11B
- $3.62B
- $2.81B
- $1.86B
- $1.21B
Frequently asked questions
Biogen (BIIB) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation